Although IV administration is not optimal for use in an outpatient population with sleepiness, these results support the further evaluation of an orally available OX2R-selective agonist in individuals with sleep disorders characterized by EDS with or without reduced orexin levels. The gene discussed is HCRTR2; the disease is Ehlers-Danlos syndrome.